<DOC>
	<DOCNO>NCT01808768</DOCNO>
	<brief_summary>To study impact alcaftadine patient treat opthalmic ocular agent ( specific topical opthalmic treatment ) allergy subspecialist outpatient setting .</brief_summary>
	<brief_title>Ocular Allergy Treatment Practical Impact Trial</brief_title>
	<detailed_description>To assess impact ocular allergy treatment patient use ophthalmic agent ( treatment ) versus alcaftadine ( Lastacaft™ )</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Alcaftadine</mesh_term>
	<criteria>1. patient age 18 old history seasonal perennial form allergic conjunctivitis skin test positive reactivity seasonal aeroallergens 2 . Total Ocular Symptom Score ( TOSS ) day enrollment 4 . 3. allergic ocular symptom past week either treat ophthalmic agent treatment . 4 . Are willing/able follow instruction study investigator his/her study staff . 5 . Have sign infromed consent approve Institutional Review Board Independent Ethics Committee . 1 . Active ocular infection ; 2 . History retinal detachment , diabetic neuropathy , progressive retinal disease ; 3 . Ocular surgical intervention within three ( 3 ) month prior visit 1 schedule study . 4 . History unstable , uncontrolled disease nature . 5 . Pregnancy lactation ; 6 . Have know hypersensitivity tp LASTACAFT™ ( alcaftadine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>